About: http://data.cimple.eu/news-article/00f19f3ed6ef8da95fd5127eaa14f8d8265b3feefc9032093ac7d0d8

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/00f19f3ed6ef8da95fd5127eaa14f8d8265b3feefc9032093ac7d0d8 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Berlin will take a stake in German biotech company CureVac, Finance Minister Peter Altmaier said Monday, months after reports the US was eyeing the firm and its under-development coronavirus vaccine. "We're sending a clear signal for CureVac here in Germany as a place to do business," Altmaier told reporters in the capital. The federal government's 300-million-euro ($337-million) investment will buy it a 23-percent stake in CureVac, based in Tuebingen in southwest Germany. Until now, billionaire Dietmar Hopp -- a co-founder of European software giant SAP -- had been the major investor, with more than 80 percent of the shares. CureVac's technology, based on molecules known as "messenger RNA" (mRNA) that are found within the body, offers "great for potential for vaccines for COVID-19 but also many other infectious diseases, as well as therapy options for many other indications," Hopp told reporters via video link. Vaccines based on mRNA "have the potential to protect people with a very low dose" and do not need to be refrigerated, acting chief executive Franz-Werner Haas said, simplifying the logistics of inoculating large numbers of people. In March, a newspaper report alleged that the US had attempted to buy exclusive rights to the CureVac's vaccine research. Though company and US officials dismissed it as unfounded, the newspaper report caused outrage in Berlin, and prompted minister Altmaier to declare that "Germany is not for sale". Germany's investment comes days after Berlin, Paris, Rome and The Hague said they had signed an agreement to procure up to 400 million doses of a potential coronavirus vaccine from pharmaceutical group AstraZeneca. The agreement calls for all EU member states to receive supplies of the vaccine as soon as it is discovered. AstraZeneca is working with Oxford University on a highly-publicised vaccine candidate, with trials on 10,000 participants getting underway. tgb/mfp/spm
schema:headline	German govt pumps 300 mln euros into vaccine firm CureVac
schema:mentions	Logistics The Hague Finance minister Rome Pharmaceutical industry University of Oxford Berlin Billionaire AstraZeneca Germany Paris Messenger RNA European Union Vaccine Coronavirus Severe acute respiratory syndrome coronavirus 2 Dietmar Hopp CureVac SAP SE Peter Altmaier Haas F1 Team
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-06-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	86 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software